The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma

Amplification of MYCN is the signature genetic aberration of 20–25% of neuroblastoma and a stratifying marker associated with aggressive tumor behavior. The detection of heterogeneous MYCN amplification (hetMNA) poses a diagnostic dilemma due to the uncertainty of its relevance to tumor behavior. He...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Bogen, Dominik, Brunner, Clemens, Walder, Diana, Ziegler, Andrea, Abbasi, Reza, Ladenstein, Ruth L., Noguera, Rosa, Martinsson, Tommy, Amann, Gabriele, Schilling, Freimut H., Ussowicz, Marek, Benesch, Martin, Ambros, Peter F., Ambros, Inge M.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Tumor Markers and Signatures
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4949549/
https://ncbi.nlm.nih.gov/pubmed/26910568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30050
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars